344 Index Name Paper ref. Name Paper ref. Kovacevic, A Tue 091, Tue 151 Kovacevic, I Tue 367 Kovacs, P Mon 027 Kovalenko, L Tue 276, Kovalev, G Wed 426 Koyama, M Thu 072 Koyama, T Tue 154 Kraahs, P Mon 229 Kraehling, JR Wed 280, Thu 252, Wed 210 Krahn, T Thu 057 Krahtz, C Mon 247 Kraneveld, AD FC09.5.2, W11.3 Krassoi, I Wed 197 Krause, D Wed 261 Krause, G Thu 087 Kraushaar, N Wed 190 Krayneva, V Mon 431 Krcmova, I Tue 222, Tue 421, Tue 240 Kreft, S Thu 359 Kreilgaard, M FC17.4.2 Krejsek, J Tue 222, Tue 421, Tue 240 Kremoser, C FC18.2.6 Krenek, P FC05.4.5, Thu 097, Mon 221 Krenek, P Mon 219 Kreuchwig, A Thu 087 Kringen, M Wed 139 Krishnan, S Mon 102 Krishnaswami, S FC07.3.3 Kristensen, AK Tue 065 Kristensen, AS Tue 080 Kristensen, J FC10.5.3 Kristensen, SD FC05.2.3 Kristensen, VN Wed 151 Kristhal, O Wed 325 Kristiansen, K Mon 224 Kristiansen, U Thu 101 Kristof, A Mon 100 Kristoffersen, T Wed 014, Wed 015 Kristova, V Tue 113 Krnic, D Mon 342, Mon 343 Krobert, KA Wed 026 Kroemer, H Tue 045 Kroemer, HK FC02.4.2, Tue 039 Kroetz, D W16.1 Kroigaard, C Wed 229, Wed 230, Wed 281, Wed 282 Krøjgaard, C Thu 259 Krombach, F Tue 227, FC16.1.5 Krook, A FC05.1.2 Kropotov, A Mon 426 Krotov, GI Wed 175 Krs, O Tue 125 Krstic-Milosevic, D Wed 387 Krüger, DB Mon 073 Kruger, D Mon 058 Kruger, HS Thu 016 Krupitza, G Thu 308 Krzan, M Tue 048 Krzan, Mojca Mon 074 Ksouda, K Wed 191 Ku, DD FC16.1.3 Ku, HC Mon 220 Ku, Y-L Wed 326 Kubes, P Tue 229 Kublickiene, K Thu 256 Kubo, K Thu 402 Kuca, K Tue 074, Tue 448 Kuca, K Tue 343, Mon 075 Kucur, M Thu 266, Mon 199 Kuczyk, M Tue 212, Tue 211, Tue 210 Kuczyk, MA FC08.3.5, Mon 247 Kudo, K Wed 186, Tue 477 Kudo, T Mon 182 Kudryavtseva, O Wed 283 Kudumija-Slijepèevic, M Wed 398 Küçük, N Tue 018 Kühn, J-P Tue 041 Kuei, C Wed 093 Kuhad, A Mon 183, Tue 344 Kukes, V Tue 129, Tue 057 Kukes, VG Thu 253 Kuki, A Tue 274 Kukkonen, J Thu 051 Kulakova, AV Tue 165 Kulkarni, SK Wed 168 Kullak-Ublick, GA FC02.4.4, Thu 435 Kumagai, Y Tue 345 Kumai, T Wed 117, Tue 492, Tue 273, Tue 337, Tue 336, Tue 483 Kumakura, Y FC17.1.2 Kumana, C Tue 346 Kumano, K Thu 285 Kumar, JK Thu 379 Kumar, V Wed 324 Kume, T Mon 424, Mon 432, Mon 464 Kummu, M Mon 063, Mon 076 Kun, A Wed 284 Kunitomo, M Thu 320, Tue 143 Kunze, G Tue 438 Kuo, H-S Wed 286 Kurahashi, C Wed 128, Wed 372 Kuramoto, N Tue 375, Wed 083 Kurata, N Thu 319, Tue 320, Thu 343, Thu 072 Kurihara, T FC03.4.5 Kuroda, Y Tue 236 Kuroiwa, K Tue 294 Kurokawa, S Tue 373 Kurose, H Thu 109 Kusljic, S Mon 240, Mon 242, Tue 416 Kusturica, J Wed 199 Kuszpit, K Tue 372 Kutcher, S Thu 394 Kuwabara, M Thu 263 Kuwamata, M Mon 307 Kuzelova, M Tue 113 Kuzmenko, M FC06.1.6 Kuzumaki, N Thu 188, Wed 065 Kvell, K Mon 401 Kvetina, J Tue 056, Tue 342, Thu 168 Kvetnansky, R Thu 039 Kvist, T Wed 084 Kwak, HC Wed 285 Kwan, A-L Mon 319, Kwan, CY Wed 194 Kwan, YW Thu 255, Wed 345, Thu 381 Kwan, Y-W Wed 244 Kwanashie, H Wed 145
Name Paper ref. Name Paper ref. Kwiecien, S Tue 463 Kwizera, EN Mon 037 Kwok, HF Thu 297 Kyselovic, J FC05.4.5, Mon 219, Thu 097, Mon 221 Kýyýcý, S Mon 156 la Cour Poulsen, L Wed 447 La Rana, G FC18.1.6 La Torre, M Thu 302 Laavola, M FC16.3.4 Labar, B Tue 304 Labarrios, F Wed 217 Lacadie, C FC14.3.3 Lacerda, RB Mon 279 Lachaux, A Mon 263 Lächelt, S Mon 059 Lackovic, Z Mon 096, W17.1 Lacoin, L Tue 092 Laconca, L Thu 440 Ladwa, S Mon 353, Mon 352 Laeremans, H Wed 085 Lafuente-de-carvalho, J FC08.2.6 Lagercrantz, H Wed 006 Laget, M FC11.3.5 Lagler, FB Thu 014, Wed 016 Lagrue-Lak-Hal, A-H Wed 196 Laguna, JC Tue 133 Lahdenranta, M Wed 444 Laher, I FC15.1.3 Lahtinen, M Thu 052 Lai, C-C Wed 192, Thu 198 Lai, X Tue 075 Laine, K Mon 144 Laitila, J Mon 380, Tue 330 Laitinen, J Mon 328 Laius, O FC04.3.4 Lakhal, M FC07.3.6, Mon 004, Mon 020, Mon 021, Mon 338, Wed 348, Thu 346 Lalic, Z Tue 304 Lalla, A Wed 129, Tue 347 Lallemand, C FC09.2.3 Lalosevic, D Wed 321 Laloux, B Mon 191 Lam, FFY Tue 417, Wed 345 Lam, KSL Mon 271, Mon 159 Lam, M Mon 242, Mon 248 Lam, TH Mon 271, Mon 159 Lamaida, E Tue 487, Mon 449 Lamandé, S W03.7 Lambert, JJ FC03.3.5 Lamminen, T Mon 215 Lampreia, F Wed 130 Lämsä, V Wed 448 Lan, X Mon 433 Lan, Xi Tue 297 Landau, A FC17.4.5, Thu 404, Thu 405 Landreth, GE FC18.3.4 Lane, G Thu 113 Lane, J Thu 410 Lane, JR FC11.2.5 Lane, K Tue 364 Lane, N Tue 124 Lane, R FC03.2.6 Lang, R Mon 242 Lang, RJ Mon 240 Lange, AJ Wed 156 Langemeijer, E Wed 086 Langer, SZ W01.3.1 Langerová, P Tue 124 Langlois, N Tue 301 Lanius, R FC17.5.3 Lantero, A Wed 087 Lanvers-Kaminsky, C FC10.4.5 Laohapand, T Thu 335 Laorden, ML Wed 087 Laosa, O Tue 348 Lapa, AJ Thu 355 LaPerle, J Mon 236 Lapeyre-Mestre, M Tue 104, Mon 129, Mon 130, FC04.3.5, Mon 124 Lapi, F Tue 093 FC04.3.6 Lapidus, N FC13.4.6 Laplanche, J-L FC01.4.4, Wed 191 Larger, M Mon 193 Laroche, A Wed 316 Larrey, D FC04.2.6, Mon 141 Larsen, A Tue 359, Tue 248, Mon 320 Larsen, AM Mon 320 Larsen, AP Wed 099 Larsen, C Mon 450, Thu 239 Larsen, F FC07.4.5 Larsson, C Mon 055 Lartaud, I Wed 244 LaRue, S Tue 301 Laruelle, M FC17.1.3 Larvin, M Wed 285, Tue 460 Lashkari, MH Mon 036 Lass, J FC10.3.6, FC04.3.4 Lassalle, R Mon 141 Lasseter, K Mon 205 Lathers, D Tue 495 Lattanzio, F Thu 110 Lau, BS Thu 297 Lau, C Mon 045 Lau, CBS Wed 345 Lau, CP Tue 346, Thu 297 Lau, CW FC15.4.7 Lau, HYA Mon 321 Lau, KM Thu 297 Lau, S Thu 280 Lau, YS Thu 219 Lau, YT Wed 388 Lau, YY Mon 228 Laudet, V FC18.4.4 Lauferon, F Tue 198 Laurie, G Thu 110 Laurikainen, T Mon 144 Laurila, J Wed 092 Laurila, Jonne M Wed 088 Laurindo, FR Wed 202 Laurindo, FRM Wed 237 Lauris, JR Tue 261 Lavhale, M FC05.2.5 Law, IKM YI.06 Law, PY Tue 135 Lawal, B Thu 332 Layegh, P Tue 052 Index 345
- Page 1:
of basic and clinical pharmacology
- Page 4 and 5:
Congress patron 2 HRH Crown Princes
- Page 6 and 7:
Congress President Kim Brøsen Secr
- Page 8 and 9:
General information Registration &
- Page 10 and 11:
Banks, currency & credit cards The
- Page 12 and 13:
Information to presenters ■ The a
- Page 14 and 15:
Hotel Bella Center Copenhagen Groun
- Page 16 and 17:
Programme at a glance Time Hall A2
- Page 18 and 19:
16 General events General events Op
- Page 20 and 21:
Programme outline Plenary lectures
- Page 22 and 23:
FC10 Drugs for half the world: Paed
- Page 24 and 25:
Tue 12:45 W13 Workshop: Novel perip
- Page 26 and 27:
W01 Pharmacology of adrenoceptors:
- Page 28 and 29:
W02 Symposium on advances in GI pha
- Page 30 and 31:
W04 Symposium: Antioxidants as ther
- Page 32 and 33:
Plenary lectures PL01 Plenary lectu
- Page 34 and 35:
FC02 Transmembrane transport: Persp
- Page 36 and 37:
FC04 Pharmacoepidemiology, current
- Page 38 and 39:
FC06 The heart gone wrong: Stabiliz
- Page 40 and 41:
FC09 Inflammation and immunopharmac
- Page 42 and 43:
W02 Symposium on advances in GI pha
- Page 44 and 45:
SS01 Sponsored symposium Sponsored
- Page 46 and 47:
W06 Workshop. Effect of disease on
- Page 48 and 49:
W08 Workshop. Identifying targets f
- Page 50 and 51:
W10 Workshop. Innovative Medicines
- Page 52 and 53:
FC01 Clinical pharmacology in the e
- Page 54 and 55:
FC03 Ion channels in analgesia and
- Page 56 and 57:
FC05 Translational science in the m
- Page 58 and 59:
FC06 The heart gone wrong: Stabiliz
- Page 60 and 61:
FC08 Development in the treatment o
- Page 62 and 63:
Plenary lectures PL04 Plenary lectu
- Page 64 and 65:
FC01 Clinical pharmacology in the e
- Page 66 and 67:
FC03 Ion channels in analgesia and
- Page 68 and 69:
FC05 Translational science in the m
- Page 70 and 71:
FC07 Simulation and data modelling
- Page 72 and 73:
FC09 Inflammation and immunopharmac
- Page 74 and 75:
W12 Workshop. Experimental pain met
- Page 76 and 77:
W14 Workshop. Translating the human
- Page 78 and 79:
W15 Workshop. The IUPHAR initiative
- Page 80 and 81:
W17 Workshop. Standards for PhD Edu
- Page 82 and 83:
W19 Workshop. Influence of degenera
- Page 84 and 85:
FC02 Transmembrane transport: Persp
- Page 86 and 87:
FC04 Pharmacoepidemiology, current
- Page 88 and 89:
FC06 The heart gone wrong: Stabiliz
- Page 90 and 91:
FC08 Development in the treatment o
- Page 92 and 93:
PL10 ASPET Plenary Lecture Chair: T
- Page 94 and 95:
FC10 Drugs for half the world: Paed
- Page 96 and 97:
FC12 Ion channelopathies: New windo
- Page 98 and 99:
FC14 Addiction and doping: Neurobio
- Page 100 and 101:
FC17 New approaches and targets in
- Page 102 and 103:
W04 Symposium: Antioxidants as ther
- Page 104 and 105:
W21 Workshop. Inflammation - here,
- Page 106 and 107:
W23 Workshop. Applying pharmacogeno
- Page 108 and 109:
W25 Workshop. High science in the l
- Page 110 and 111:
W27 Workshop. Approaches to medicin
- Page 112 and 113:
FC11 G protein-coupled 7TM receptor
- Page 114 and 115:
FC13 Maximising benefits and minimi
- Page 116 and 117:
FC15 Endothelium in Health and dise
- Page 118 and 119:
FC17 New approaches and targets in
- Page 120 and 121:
FC18 Nuclear receptor targets for t
- Page 122 and 123:
PL16 Plenary Lecture Supported by a
- Page 124 and 125:
FC11 G protein-coupled 7TM receptor
- Page 126 and 127:
FC13 Maximising benefits and minimi
- Page 128 and 129:
FC15 Endothelium in Health and dise
- Page 130 and 131:
FC17 New approaches and targets in
- Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
- Page 134 and 135:
W30 Workshop. Is eNOS still a valid
- Page 136 and 137:
W32 Workshop. The good, the bad and
- Page 138 and 139:
W34 Workshop. State-of-the-art of b
- Page 140 and 141:
FC10 Drugs for half the world: Pedi
- Page 142 and 143:
FC12 Ion channelopathies: New windo
- Page 144 and 145:
FC14 Addiction and doping: Neurobio
- Page 146 and 147:
FC16 Natural products: Past and fut
- Page 148 and 149:
FC18 Nuclear receptor targets for t
- Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
- Page 152 and 153:
FC11 G protein-coupled 7TM receptor
- Page 154 and 155:
FC13 Maximising benefits and minimi
- Page 156 and 157:
FC15 Endothelium in health and dise
- Page 158 and 159:
FC17 New approaches and targets in
- Page 160 and 161:
158
- Page 162 and 163:
FC01 Clinical pharmacology in the e
- Page 164 and 165:
FC01 Clinical pharmacology in the e
- Page 166 and 167:
FC02 Transmembrane transport: Persp
- Page 168 and 169:
FC03 Ion channels in analgesia and
- Page 170 and 171:
W12 Experimental pain methods in de
- Page 172 and 173:
FC04 Pharmacoepidemiology, current
- Page 174 and 175:
FC05 Translational science in the m
- Page 176 and 177:
FC05 Translational science in the m
- Page 178 and 179:
FC06 The heart gone wrong; stabiliz
- Page 180 and 181:
FC07 Simulation and data modelling
- Page 182 and 183:
FC08 Developments in the treatment
- Page 184 and 185:
FC09 Inflammation and immunopharmac
- Page 186 and 187:
FC09 Inflammation and immunopharmac
- Page 188 and 189:
FC09 Inflammation and immunopharmac
- Page 190 and 191:
FC13 Maximising benefits and minimi
- Page 192 and 193:
FC13 Maximising benefits and minimi
- Page 194 and 195:
W03 Targeting TRP channels for pain
- Page 196 and 197:
W19 Influence of degeneration and r
- Page 198 and 199:
W19 Influence of degeneration and r
- Page 200 and 201:
W20 Pharmacology education for a su
- Page 202 and 203:
FC01 Clinical pharmacology in the e
- Page 204 and 205:
FC02 Transmembrane transport: Persp
- Page 206 and 207:
FC02 Transmembrane transport: Persp
- Page 208 and 209:
FC04 Pharmacoepidemiology, current
- Page 210 and 211:
FC05 Translational science in the m
- Page 212 and 213:
FC05 Translational science in the m
- Page 214 and 215:
FC06 The heart gone wrong; stabiliz
- Page 216 and 217:
FC07 Simulation and data modelling
- Page 218 and 219:
FC08 Developments in the treatment
- Page 220 and 221:
FC09 Inflammation and immunopharmac
- Page 222 and 223:
FC09 Inflammation and immunopharmac
- Page 224 and 225:
FC09 Inflammation and immunopharmac
- Page 226 and 227:
FC13 Maximising benefits and minimi
- Page 228 and 229:
FC13 Maximising benefits and minimi
- Page 230 and 231:
FC19 General session Tue 361 Analge
- Page 232 and 233:
FC19 General session - Biologics Tu
- Page 234 and 235:
FC19 General session - Haematology
- Page 236 and 237:
FC19 General session - oncology Tue
- Page 238 and 239:
FC19 General session - oncology Tue
- Page 240 and 241:
FC19 General session - Toxicology T
- Page 242 and 243:
W02 Symposium on advances in GI pha
- Page 244 and 245:
W11 New opportunities in the pharma
- Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
- Page 248 and 249:
FC10 Drugs for half the world: Paed
- Page 250 and 251:
FC11 G protein-coupled 7TM receptor
- Page 252 and 253:
FC11 G protein-coupled 7TM receptor
- Page 254 and 255:
FC12 Ion channelopathies: New windo
- Page 256 and 257:
FC13 Maximising benefits and minimi
- Page 258 and 259:
FC13 Maximising benefits and minimi
- Page 260 and 261:
FC14 Addiction and doping: Neurobio
- Page 262 and 263:
FC15 Endothelium in health and dise
- Page 264 and 265:
FC15 Endothelium in health and dise
- Page 266 and 267:
FC15 Endothelium in health and dise
- Page 268 and 269:
W30 Is eNOS Still a valid therapeut
- Page 270 and 271:
FC16 Natural products: Past and fut
- Page 272 and 273:
FC16 Natural products: Past and fut
- Page 274 and 275:
FC16 Natural products: Past and fut
- Page 276 and 277:
FC17 New approaches and targets in
- Page 278 and 279:
FC17 New approaches and targets in
- Page 280 and 281:
W34 State-of-the-art of basic and c
- Page 282 and 283:
FC10 Drugs for half the world: Paed
- Page 284 and 285:
FC11 G protein-coupled 7TM receptor
- Page 286 and 287:
FC11 G protein-coupled 7TM receptor
- Page 288 and 289:
FC11 G protein-coupled 7TM receptor
- Page 290 and 291:
FC13 Maximising benefits and minimi
- Page 292 and 293:
FC13 Maximising benefits and minimi
- Page 294 and 295:
W29 New horizons in therapeutic dru
- Page 296 and 297: FC14 Addiction and doping: Neurobio
- Page 298 and 299: FC15 Endothelium in health and dise
- Page 300 and 301: FC15 Endothelium in health and dise
- Page 302 and 303: FC15 Endothelium in health and dise
- Page 304 and 305: FC16 Natural products: Past and fut
- Page 306 and 307: FC16 Natural products: Past and fut
- Page 308 and 309: FC16 Natural products: Past and fut
- Page 310 and 311: FC16 Natural products: Past and fut
- Page 312 and 313: FC17 New approaches and targets in
- Page 314 and 315: FC18 Nuclear receptor targets for t
- Page 316 and 317: 314 Index Name Paper ref. Name Pape
- Page 318 and 319: 316 Index Name Paper ref. Name Pape
- Page 320 and 321: 318 Index Name Paper ref. Name Pape
- Page 322 and 323: 320 Index Name Paper ref. Name Pape
- Page 324 and 325: 322 Index Name Paper ref. Name Pape
- Page 326 and 327: 324 Index Name Paper ref. Name Pape
- Page 328 and 329: 326 Index Name Paper ref. Name Pape
- Page 330 and 331: 328 Index Name Paper ref. Name Pape
- Page 332 and 333: 330 Index Name Paper ref. Name Pape
- Page 334 and 335: 332 Index Name Paper ref. Name Pape
- Page 336 and 337: 334 Index Name Paper ref. Name Pape
- Page 338 and 339: 336 Index Name Paper ref. Name Pape
- Page 340 and 341: 338 Index Name Paper ref. Name Pape
- Page 342 and 343: 340 Index Name Paper ref. Name Pape
- Page 344 and 345: 342 Index Name Paper ref. Name Pape
- Page 348 and 349: 346 Index Name Paper ref. Name Pape
- Page 350 and 351: 348 Index Name Paper ref. Name Pape
- Page 352 and 353: 350 Index Name Paper ref. Name Pape
- Page 354 and 355: 352 Index Name Paper ref. Name Pape
- Page 356 and 357: 354 Index Name Paper ref. Name Pape
- Page 358 and 359: 356 Index Name Paper ref. Name Pape
- Page 360 and 361: 358 Index Name Paper ref. Name Pape
- Page 362 and 363: 360 Index Name Paper ref. Name Pape
- Page 364 and 365: 362 Index Name Paper ref. Name Pape
- Page 366 and 367: 364 Index Name Paper ref. Name Pape
- Page 368 and 369: 366 Index Name Paper ref. Name Pape
- Page 370 and 371: 368 Index Name Paper ref. Name Pape
- Page 372 and 373: 370 Index Name Paper ref. Name Pape
- Page 374 and 375: 372 Index Name Paper ref. Name Pape
- Page 376 and 377: 374 Index Name Paper ref. Name Pape
- Page 378 and 379: 376 Index Name Paper ref. Name Pape
- Page 380 and 381: 378 Index Name Paper ref. Name Pape
- Page 382 and 383: 380 Index Name Paper ref. Name Pape
- Page 384 and 385: 382 Notes Notes
- Page 386: Final Programme printed in Singapor